Lewy Body Dementia Diagnoses and Management

Lewy body dementia is a neurodegenerative disorder characterised by the accumulation of alpha-synuclein inclusions in cortical and subcortical neurons, manifesting as cognitive fluctuations, vivid visual hallucinations and parkinsonian motor signs. Diagnosis rests on a combination of clinical assessment—including detailed neuropsychological testing and structured history taking—and supportive biomarkers. Core features encompass spontaneous parkinsonism, recurrent well-formed visual hallucinations and pronounced fluctuations in attention and alertness. Ancillary investigations such as dopamine transporter imaging, cardiac metaiodobenzylguanidine scintigraphy and quantitative electroencephalography improve diagnostic confidence, particularly in early or prodromal stages. Management aims to balance cognitive, motor and neuropsychiatric symptoms while minimising adverse effects. Cholinesterase inhibitors constitute first-line therapy for cognitive and behavioural disturbances, whereas cautiously dosed levodopa may alleviate rigidity and bradykinesia. Antipsychotic agents are generally avoided due to heightened sensitivity; if required, low-dose atypical medications are preferred. Non-pharmacological interventions—including cognitive stimulation, physical rehabilitation and caregiver education—are integral to comprehensive care. Emerging strategies targeting synucleinopathy, tau co-pathology and neuroinflammation offer prospects for disease modification. Delivery of multidisciplinary care, involving neurology, psychiatry, geriatrics and allied health professionals, is essential to address the multifaceted needs of patients and their families worldwide.

Research from Nature Portfolio

No recent Nature Portfolio content available.

Lewy Body Dementia Diagnoses and Management publication trend

The graph below shows the total number of articles in lewy body dementia diagnoses and management across all publications each year (not limited to Nature Index journals).

Technical terms

Alpha-synuclein: A neuronal protein prone to misfolding and aggregation, forming Lewy bodies that drive synaptic dysfunction and neurodegeneration.

Cholinesterase inhibitor: A class of drugs that enhance cholinergic transmission by inhibiting the enzyme acetylcholinesterase, used to ameliorate cognitive and behavioural symptoms.

Dopamine transporter imaging (DAT-SPECT): A single-photon emission technique that evaluates presynaptic dopaminergic terminal integrity in the striatum, aiding differential diagnosis of parkinsonian syndromes.

Mild cognitive impairment with Lewy bodies (MCI-LB): A prodromal phase marked by mild cognitive deficits and at least one core clinical feature of Lewy body dementia, preceding the onset of overt dementia.

Fluorodeoxyglucose positron emission tomography (FDG-PET): A metabolic imaging modality that measures regional cerebral glucose utilisation, detecting hypometabolism patterns associated with synucleinopathy and co-pathologies.

References

1. Dementia with lewy bodies patients with high tau levels display unique proteome profiles. Molecular Neurodegeneration (2024).
2. Research diagnostic criteria for mild cognitive impairment with Lewy bodies: A systematic review and meta‐analysis. Alzheimer's & Dementia (2023).
3. Genetic analysis of the X chromosome in people with Lewy body dementia nominates new risk loci. npj Parkinson's Disease (2024).